Development and characterization of proteasome inhibitors

Methods Enzymol. 2005:399:585-609. doi: 10.1016/S0076-6879(05)99039-3.

Abstract

Although many proteasome inhibitors have been either synthesized or identified from natural sources, the development of more sophisticated, selective proteasome inhibitors is important for a detailed understanding of proteasome function. We have found that antitumor natural product epoxomicin and eponemycin, both of which are linear peptides containing a alpha,beta-epoxyketone pharmacophore, target proteasome for their antitumor activity. Structural studies of the proteasome-epoxomicin complex revealed that the unique specificity of the natural product toward proteasome is due to the alpha,beta-epoxyketone pharmacophore, which forms an unusual six-membered morpholino ring with the amino terminal catalytic Thr-1 of the 20S proteasome. Thus, we believe that a facile synthetic approach for alpha,beta-epoxyketone linear peptides provides a unique opportunity to develop proteasome inhibitors with novel activities. In this chapter, we discuss the detailed synthetic procedure of the alpha',beta'-epoxyketone natural product epoxomicin and its derivatives.

MeSH terms

  • Chromatography, High Pressure Liquid
  • Drug Design
  • Kinetics
  • Oligopeptides / chemistry
  • Oligopeptides / isolation & purification
  • Oligopeptides / pharmacology
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / isolation & purification
  • Protease Inhibitors / pharmacology*
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors*
  • Stereoisomerism
  • Structure-Activity Relationship

Substances

  • Oligopeptides
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Proteasome Endopeptidase Complex
  • epoxomicin